ChromoGenics Q3 2023: Robust order intake and cost reduction continue. But weak sales in the quarter - Redeye

Redeye comments on ChromoGenics Q3 2023 report. The cost reduction efforts made throughout the quarter resulted in a smaller loss than anticipated. Although sales were significantly lower, a robust order intake provides a positive outlook

Länk till analysen i sin helhet: https://www.redeye.se/research/944991/chromogenics-q3-2023-robust-order-intake-and-cost-reduction-continue-but-weak-sales-in-the-quarter?utm_source=finwire&utm_medium=RSS